Versuchen GOLD - Frei

Leprosy Isn't Over: South-East Asia's Unfinished Fight

BioSpectrum Asia

|

BioSpectrum Asia Feb 2026

As we commemorate World Leprosy Day on January 25, the global community is oldest diseases-has not yet been consigned to history.

- Narayan Kulkarni

Nowhere is this more evident than in the South-East Asia Region, which continues to shoulder the largest share of the global leprosy burden. While remarkable progress has been made, the persistence of new cases underscores an urgent truth: leprosy is curable, but elimination demands far more than medicine alone.

South-East Asia accounts for the majority of newly detected leprosy cases worldwide. According to a WHO report released on January 23, 2026, India and Indonesia continue to report more than 10,000 new cases annually, while countries such as Bangladesh, Myanmar, Nepal and Sri Lanka report thousands more. This mirrors global trends from 2024, when Brazil, India and Indonesia together accounted for the highest number of cases, even as 55 countries reported zero cases. Poverty, overcrowded living conditions, limited access to health services and social marginalisation continue to create fertile ground for transmission.

WEITERE GESCHICHTEN VON BioSpectrum Asia

BioSpectrum Asia

BioSpectrum Asia

The Race to Build Singapore's Biotech Unicorns

MIRXES, known for its work in early cancer detection and backed by A*STAR and the National University of Singapore, became Southeast Asia's first biotech unicorn when it listed on the Hong Kong Exchange in 2025.

time to read

5 mins

BioSpectrum Asia Feb 2026

BioSpectrum Asia

BIRAC inks Letter of Intent with Global Antibiotic Research & Development Partnership

Biotechnology Industry Research Assistance Council (BIRAC), under the Department of Biotechnology (DBT), Government of India, has announced a Letter of Intent (LOI) with the Global Antibiotic Research & Development Partnership (GARDP), a Swiss not-forprofit organisation that develops new antibiotic treatments for drug-resistant bacterial infections that pose the greatest threat to human health.

time to read

1 min

BioSpectrum Asia Feb 2026

BioSpectrum Asia

BioSpectrum Asia

"Neuroinflammation is not only a hallmark of Alzheimer's disease but a key pathological feature in other neurodegenerative disorders"

As dementia becomes the leading cause of death in Australia and Alzheimer’s disease continues to affect millions worldwide, the urgency for fundamentally new treatment strategies has never been clearer.

time to read

4 mins

BioSpectrum Asia Feb 2026

BioSpectrum Asia

Leprosy Isn't Over: South-East Asia's Unfinished Fight

As we commemorate World Leprosy Day on January 25, the global community is oldest diseases-has not yet been consigned to history.

time to read

2 mins

BioSpectrum Asia Feb 2026

BioSpectrum Asia

BioSpectrum Asia

"Absence of a widespread infectious disease emergency in 2025 has hindered progress in combating AMR"

After decades of incremental antibiotic innovation, antimicrobial resistance (AMR) is outpacing our ability to respond, and 2026 may mark a breaking point.

time to read

5 mins

BioSpectrum Asia Feb 2026

BioSpectrum Asia

BioSpectrum Asia

The Strategic Rise of India's Deep-Science Economy

India is emerging as a powerful hub for deep science and biotechnology, driven by favourable geopolitics, a large domestic market, strong pharmaceutical and chemicals infrastructure, and supportive government policies.

time to read

4 mins

BioSpectrum Asia Feb 2026

BioSpectrum Asia

BioSpectrum Asia

Japan strengthening biopharma capabilities

Asia's biopharma landscape is shifting rapidly toward innovation, with countries such as South Korea, Singapore, India, and Taiwan advancing R&D capabilities.

time to read

7 mins

BioSpectrum Asia Feb 2026

BioSpectrum Asia

BioSpectrum Asia

Cancer Diagnosis, Accelerated by AI

Cancer remains a leading cause of death worldwide, with Asia bearing a disproportionate burden.

time to read

13 mins

BioSpectrum Asia Feb 2026

BioSpectrum Asia

BioSpectrum Asia

Beyond Companion Diagnostics: How Biomarkers and Digital Technologies Will Reshape Oncology Care in Asia by 2026

The oncology landscape in Asia stands at a critical juncture.

time to read

5 mins

BioSpectrum Asia Feb 2026

BioSpectrum Asia

BioSpectrum Asia

Pharma M&A set to boom in 2026

After years of unspectacular Mergers and Acquisitions (M&A) activity, 2025 recorded some of the largest pharma deals.

time to read

3 mins

BioSpectrum Asia Feb 2026

Listen

Translate

Share

-
+

Change font size